Navigation Links
China RuiTai Reports Fiscal Year 2007 Financial Results
Date:4/16/2008

TAI'AN, Shandong, China, April 16 /Xinhua-PRNewswire-FirstCall/ -- China RuiTai International Holdings Co., Ltd. (OTC Bulletin Board: CRUI) (''China RuiTai'' or ''the Company''), a leading producer and distributor of cellulose ether products in the People's Republic of China (''PRC''), today announced its financial results for the fiscal year ended December 31, 2007.

Fiscal Year 2007 Highlights

-- Sales increased 36.7% to $38.4 million

-- Gross profit increased 33.4% to $11.9 million

-- Gross profit margin was 31.0%

-- Operating income increased 52.3% to $8.1 million

-- Operating margin improved 216 basis points to 21.1%

-- Net income increased 62.2% to $4.9 million, or $0.23 per basic and

fully diluted share

-- Completed a production line to increase production capacity to 10,000

metric ton per year

-- Became a public company through a share exchange transaction in August

2007

''We are pleased to see continuous strong growth as our cellulose ether products continue to receive wide acceptance while meeting the worldwide expanding demand,'' commented Dianmin Ma, Chief Executive Officer and Chairman of China RuiTai. ''In 2007, we exported about 2,400 metric tons of cellulose ether products to foreign markets in the United States, Europe, India, the Middle East, and South East Asia. Our sales in the domestic market were about twice that of our international market. We expect further growth in the domestic and international markets in 2008 and beyond.''

Full Year 2007 Results

During the year ended December 31, 2007, sales were $38.4 million, an increase of 36.7% from $28.2 million for 2006. This was primarily due to increased order volumes from the Company's existing customers. Hydroxypropyl Methyl Cellulose (HPMC) remained the Company's top-selling product, accounting for 68.4% in 2007, compared to 66.0% in 2006.

Gross profit in 2007 was $11.9 mill
'/>"/>

SOURCE China RuiTai International Holdings Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...SHINGTON,Nov.24/PRNewswire/--TheUnionLaborLifeInsu...hasalignedwithVSP(®),()thenation,slargestvisi...oninsuranceproductstounions,uniontrustfunds,unione...ccesspointsofferingservicesincludingcomprehensivee...nderstandhowimportantqualityeyecareis,"statedBruce...
(Date:11/24/2009)...s that quitting improves heart prospects, but canc...althDay News) -- A new study offers yet more proof...m heart disease and cancer. , Researchers follo...mokers, formers smokers and nonsmokers for three y...times more likely to die of cancer, 2.26 times mor...
(Date:11/24/2009)...x as an example, study finds no added use but high... News) -- Direct-to-consumer drug ads may contribu...udy that examined sales of the widely used antipla... of data from 1999 to 2005 for 27 state Medicaid p...for clopidogrel did not increase people,s use of t...
(Date:11/24/2009)...WYORK,Nov.24/PRNewswire/--TheGuardianLifeInsurance...feinsurersandaleadingproviderofemployeebenefitsfor...mpanywillcontinuetofollowitscurrentinsurancecovera...esareconsistentwiththeAmericanCancerSocietyandAmer...graphyscreenings. ,, Recently,TheU.S.Preventive...
(Date:11/24/2009)...lease is available in French and Spanish . ,...e found a suicide gene, called ,gene E, which lea...t, lung and colon cancer, and prevents their growt... to fight cancer can reduce the potent drugs that ...ive treatment for cancer. , This research was co...
Breaking Medicine News(10 mins):Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Smokers Double Their Risk for Heart Disease 2Health News:Advertising to Consumers May Raise Drug Prices 2Health News:Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage 2
...shington Joins Nationwide Campaign to Close the Ga...-Income Women and Women of Color, SEATTLE, Nov. 8...cancer incidence in the United States. Tonight, th...t for,screening programs for low-income women and ...
...rmatologists Can Help Manage the Effects of Stress... Nails, NEW YORK, Nov. 8 Pending job cuts at...orce. An unexpected surgery. What do,they all have...atologic problems, such as acne, brittle nails or ...
...MBURG, Germany and OXFORD, England, November 8 /PR...Exchange: EVT) will report its financial,results f...er 2007. The Company is going to hold a conferenc.... US time (East Coast), Conference call numbers: ...
.... Auayporn Nademanee of City of Hope leads study s...el therapy, ARCADIA, Calif. and DUARTE, Calif., N...s selected an abstract written by Dr.,Auayporn Nad...obal Medical Director for StemCyte, as one of four...
...THESDA, Md., Nov. 8 World Diabetes Day, November ... in more than 160 countries,and by others with an ...on,of diabetes in children and adolescents," provi... National Institutes of Health (NIH), researchers ...
...inful Eye Condition Can Occur in Up to 40 Percent ...s (Spinal Arthritis), ABBOTT PARK, Ill., Nov. 8 ...eated with Abbott,s HUMIRA(R) showed,a decrease in...spine, and may also be associated with other infla...
Other Medicine News:Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:Feeling Stressed? 2Health News:Feeling Stressed? 3Health News:Feeling Stressed? 4Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 2Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 3Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 4Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 2Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 4Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 5Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 6
(Date:11/24/2009)... ,, RALEIGH,N.C.,Nov.24/PRNewswire/--Pharmac...ningsolutionsforthepharmaceuticalandbiotechindustr...pitalMarketplace .Thenew HospitalMarketplace e-cou...sExcellence(TM) series,acomprehensiveseriesofe-cou...edmanagedmarketsknowledgeforcommercialprofessional...
(Date:11/24/2009)... ,, WASHINGTON,Nov.24/PRNewswire-USNewswire/...ompaniesaretesting97medicinesandvaccinestotreatorp...reportreleasedtodaybythePharmaceuticalResearchandM...anniversaryof"WorldAIDSDay"-aglobalawarenesscampai...ealthonProgrammesforAIDSPrevention. ,, "Wearegr...
(Date:11/24/2009)... ,, BEIJING,Nov.24/PRNewswire-Asia-FirstCall...S)("Lotus"orthe"Company")agrowingdeveloperand,prod...fpharmaceutical,productsinthePeople,sRepublicChina...memberoftheBeijingpharmaceuticaldelegation. ,...alConventionCenter,Chengdu ,, TheBeijingdeleg...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 1Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8
...un 28, 2007 - Cytogen,Corporation (NASDAQ: CYTO) r...n study evaluating QUADRAMET(R) (samarium Sm-153,l...b (Velcade(R),Millennium Pharmaceuticals, Inc.) i...om 33 patients were presented today in a,poster ti...ium,(Sam) in Multiple Myeloma," by James Berenson,...
...ed with VELCADE, lenalidomide,and dexamethasone , ...llennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) toda...r clinical trials of VELCADE based,therapies that ...ission / complete response(1) (CR) rates in newly ...ta were presented at the,prestigious 11th Internat...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
The Link Ribbed Hip Stem
The SG stem
The KR stem
The MY stem
Medicine Products: